Factor Xa Inhibitor - Market Insight, Epidemiology And Market Forecast - 2034

Published Date : 2024
Pages : 200
Region : United States, Japan, EU4 & UK

Share:

Factor Xa Inhibitor Market

DelveInsight’s “Factor Xa Inhibitors Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the Factor Xa Inhibitors, historical and Competitive Landscape as well as the Factor Xa inhibitor market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Factor Xa Inhibitors market report provides current treatment practices, market share of individual therapies, and current and forecasted 7MM Factor Xa Inhibitor market size from 2020 to 2034. The report also covers current Factor Xa Inhibitors treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Study Period

2020–2034

Forecast Period

2025–2034

Geographies Covered

US, EU4 (Germany, France, Italy, and Spain) the UK, and Japan

Factor Xa Inhibitors Epidemiology

Segmented by:

Factor Xa Inhibitors Key Companies

Factor Xa Inhibitors Key Therapies

Factor Xa Inhibitors Market

Segmented by:

Analysis

Factor Xa Inhibitors Understanding

Factor Xa Inhibitors Overview

Factor Xa inhibitors are anticoagulants used to treat and prevent blood clots in veins, and to prevent stroke and embolism in individuals with atrial fibrillation. Factor Xa, a serine protease, plays a crucial role in the coagulation pathway by cleaving prothrombin to generate thrombin, a key step in blood clot formation. Targeting factor Xa is considered advantageous for controlling thrombogenic events as it requires lower plasma levels of the inhibitor, potentially offering a better therapeutic index for anticoagulation with reduced risk of bleeding.

Inhibition of clotting factor Xa has been evaluated as a potential target for anticoagulation therapy with the hypothesis that using target-specific therapy will alleviate some of the dosing variability observed with the vitamin K antagonist. Three-factor Xa inhibitors are currently indicated for use in non-valvular atrial fibrillation. Similar to the vitamin K antagonist, warfarin, all of the factor Xa inhibitors are administered orally. The Factor Xa inhibitors have several approved indications for use including stroke or systemic embolism risk reduction in patients with non-valvular atrial fibrillation, treatment and reduction of recurrent deep vein thrombosis and pulmonary embolism, and VTE prophylaxis following knee or hip replacement surgery.

Further details related to country-based variations are provided in the report…

Factor Xa Inhibitors Epidemiology

The factor Xa inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for factor Xa inhibitors, total eligible patient pool for factor Xa inhibitors in selected indications, total treated cases in selected indications for factor Xa inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

Factor Xa Inhibitors Drug Chapters

The drug chapter segment of the factor Xa inhibitors reports encloses a detailed analysis of factor Xa inhibitor-marketed drugs. It also helps understand the factor Xa inhibitor’s clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

SAVAYSA/LIXIANA (edoxaban): Daiichi Sankyo

SAVAYSA is an orally active anticoagulant that specifically, reversibly, and directly inhibits factor Xa, and is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Edoxaban, marketed as LIXIANA in Japan, Europe, and Asia, and as SAVAYSA in the US that succeeded olmesartan following its loss of exclusivity; since its launch, the company has steadily increased market share, particularly in Japan, Europe, and Asia, and is now focusing on strengthening life-cycle management and enhancing product awareness.

In February 2025, LIXIANA was approved in Japan for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH), expanding its therapeutic indications.

In June 2015, Daiichi Sankyo announced that the European Commission granted marketing authorisation for LIXIANA for the prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation (NVAF)who have one or more risk factors, as well as for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism.

LIXIANA was first approved in Japan in April 2011 for VTE prevention after major orthopedic surgery and later, in September 2014, for stroke prevention in NVAF and for the treatment and prevention of recurrent VTE.

ELIQUIS (apixaban): Bristol-Myers Squibb

ELIQUIS is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, Eliquis decreases thrombin generation and thus blood clot formation. ELIQUIS is a prescription medicine approved for multiple indications in the US, the European Union (which includes 28 member states plus Iceland and Norway) and Japan, as well as a number of other countries around the world based on efficacy and safety data, including results from seven Phase III clinical trials. In Japan, ELIQUIS is approved for the prevention of stroke and systemic embolism in patients with NVAF. ELIQUIS is also approved in Japan for the treatment of VTE, which includes DVT, and pulmonary embolism, and prevention of recurrent DVT and pulmonary embolism following initial therapy.

The company expects generic entry for ELIQUIS in the US starting April 2028, while in Europe, although patent challenges are ongoing in certain countries, key market patent expirations are anticipated in the second half of 2026.

Table 1: Comparison of Key Marketed Drugs

Product

Company

RoA

Approval

Indication (US FDA)

ELIQUIS

(apixaban)

Bristol-Myers Squibb

Oral

US: 2012

EU: 2012

JP: 2012

  • To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
  • For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
  • For the treatment of DVT and PE, and the reduction in the risk of recurrent DVT and PE following initial therapy.

SAVAYSA/ LIXIANA

(edoxaban)

Daiichi Sankyo

Oral

US: 2015

EU: 2015

JP: 2014

  • To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF)
  • For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant

XARELTO (rivaroxaban)

Bayer

Oral

US: 2011

EU: 2008

JP: 2022

  • Stroke prevention in NVAF
  • Treatment of PE/DVT and prevention of recurrent VTE
  • Prevention of Atherothrombotic Events in Peripheral Artery Disease
  • Prevention of Atherothrombotic Events in Coronary Artery Disease
  • Secondary prevention in ACS
  • Prevention of VTE after elective hip replacement surgery
  • Prevention of VTE after elective knee replacement surgery

Note: Detailed current therapies assessment will be provided in the full report.

Factor Xa Inhibitors Market Outlook

Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for many indications. Currently, available DOACs include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa. A new class of DOACs is under development. These new DOACs, which include asundexian and milvexian, inhibit FXIa, which is positioned in the intrinsic pathway of coagulation. Anticoagulants that target FXIa have the potential to be safer than the current DOACs because there is emerging evidence that FXI is essential for thrombosis but mostly dispensable for hemostasis. Hence there is almost no development in the field of Factor Xa Inhibitors.

Drug Class Insights

Factor Xa inhibitors are anticoagulant drugs that target and inhibit factor Xa, a crucial enzyme in the coagulation process. By blocking this enzyme, they prevent thrombin and fibrin clot formation, thereby lowering the risk of conditions like stroke and venous thromboembolism. Commonly used oral agents in this class include XARELTO, ELIQUIS, and SAVAYSA. These medications provide benefits such as consistent dosing, quick onset of action, and minimal dietary or drug interactions, making them favorable alternatives to warfarin. They are primarily prescribed for atrial fibrillation, deep vein thrombosis, and pulmonary embolism. However, they can be expensive and may require dosage adjustments in patients with impaired kidney function. In cases of major bleeding, reversal agents like andexanet alfa are available.

Factor Xa Inhibitors Market Outlook

The market for factor Xa inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed due to advancement in the indications related to factor Xa inhibitors. The growing awareness of factor Xa, and the increasing number of factor Xa inhibitors that are under clinical trials and filed for approval by various companies.

Currrently the market of factor Xa inhibitors contain some of the approved therapies such as XARELTO, ELIQUIS, and SAVAYSA. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for many indications. Currently, available DOACs include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa. Factor Xa inhibitors offer significant advantages, including fixed oral dosing, fewer drug and food interactions, and lower risk of intracranial bleeding compared to warfarin, making them more convenient and safer for many patients. Their growing use in atrial fibrillation, DVT, and stroke prevention, supported by clinical guidelines and innovation in reversal agents, is driving market growth. However, challenges remain, including high drug and reversal costs, bleeding risks (especially gastrointestinal), and emerging competition from newer anticoagulant classes like factor XI inhibitors. Additionally, generic entry and access limitations in lower-income regions may impact market dynamics.

The withdrawal of BEVYXXA (betrixaban) negatively impacted market diversity and limited treatment options for extended VTE prophylaxis in hospitalized patients, highlighting the challenges of sustaining newer drugs in a highly competitive anticoagulant market.

Note: Detailed current therapies assessment will be provided in the full report of Factor Xa Inhibitors

Factor Xa Inhibitors Drugs Uptake

This section focuses on the uptake rate of potential approved drugs of factor Xa inhibitors.

Factor Xa Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic approved candidates and analyzes key players involved in developing targeted therapeutics.

The availability of numerous drugs is expected to create significant growth opportunities for the factor Xa inhibitor′s market over the forecast period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for factor Xa inhibitor therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on factor Xa inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Baptist Health Medical Group and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or factor Xa inhibitors market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

KOL Views

“Currently available Factor Xa inhibitors have demonstrated similar efficacy and safety to warfarin in clinical trials, supporting their use as effective and reliable treatment options for patients with nonvalvular atrial fibrillation.”

MD, Wingate University, US

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The abstract list is not exhaustive, will be provided in the final report

Scope of the Report

Factor Xa Inhibitors Report Insights

Factor Xa Inhibitors Report Key Strengths

Factor Xa Inhibitors Report Assessment

Key Questions

Reasons to buy

Tags:

  • Factor Xa Inhibitor market
  • Factor Xa Inhibitor market research
  • Factor Xa Inhibitor market insight
  • Factor Xa Inhibitor market trends